Additional therapy may be needed for patients with advanced bladder cancers that are surgically removed. A five-year, international study validated the use of a marker panel to predict which patients are more likely to have a recurrence of cancer after bladder removal. Those patients were thus identified as good candidates for follow-up chemotherapy.
These findings are important because additional molecular information could help patients with bladder cancer and their physicians decide whether administering further toxic chemotherapy is worth the risk, said primary investigator Yair Lotan, MD, of the University of Texas Southwestern Medical Center. The study was published in European Urology (2013; doi: 10.1016/j.eururo.2013.03.043).
Bladder cancer is the fourth most common cancer diagnosed in men, according to the American Cancer Society. The ACS estimates that more than 72,500 cases will be diagnosed in the United States this year, and that more than 15,200 people will die from the disease in 2013.
Patients with muscle-invasive bladder cancer typically are treated by removing all or part of the bladder (a cystectomy procedure) but are infrequently given additional chemotherapy, despite an overall relapse rate of one in every three cases.
Using five commercially available markers and the tissues of patients who had their bladders removed, researchers monitored a group of 216 patients to track if their cancers recurred.
When controlled for pathologic factors such as stage, grade, lymphovascular invasion, lymph node status, surgical margin status, and whether the patients had already received chemotherapy, the number of altered biomarkers were found to be an independent predictor of recurrence and cancer-specific mortality, the researchers found.
“It is well known that bladder cancer tumors have certain molecular alterations, but the problem is that there has been little data regarding which patients should get additional therapy, especially if there is no radiologic or pathologic evidence that the cancer has spread beyond the bladder,” Lotan said. “This situation exists despite the fact that approximately 35% of patients treated by cystectomy develop metastatic disease and many of these individuals die of their disease.”
The investigation’s goal was to establish whether molecular markers that are involved in cell cycle regulation and proliferation could help identify those patients at higher risk for recurrence or metastasis following bladder-cancer surgery, Lotan said.
The next steps will be to try to incorporate the molecular marker panel into clinical practice.